TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
10x Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$69.89+0.03 (+0.04%)
Close on Oct 19, 2026
- Market cap
- $9.08B
- P/E (TTM)
- –
- Dividend yield
- –
10x Genomics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Laboratory Analytical Instruments companies for comparison
Valuation
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Market Cap | $9.11B | $230.55M |
| Enterprise Value | $8.55B | $202.97M |
| PS Ratio | 14.76 | 3.10 |
| PB Ratio | 11.03 | 3.04 |
| P/TBV Ratio | 12.02 | 4.43 |
| P/FCF Ratio | 74.99 | 27.30 |
| P/OCF Ratio | 71.65 | 22.47 |
Enterprise value
| Measure | 10x Genomics | Industry median |
|---|---|---|
| EV / Sales | 13.87 | 2.91 |
| EV / FCF | 70.44 | 27.89 |
Income (trailing twelve months)
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Revenue | $616.91M | $102.39M |
| Gross Profit | $432.03M | $60.36M |
| Operating Income | -$88.38M | -$4.31M |
| Pretax Income | -$74.89M | -$2.37M |
| Net Income | -$75.13M | -$6.57M |
| EBITDA | -$48.40M | -$1.98M |
| EPS (Diluted) | -$0.59 | -$0.08 |
Margins
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Gross Margin | 70.0% | 55.2% |
| Operating Margin | -14.3% | -6.04% |
| Pretax Margin | -12.1% | -4.11% |
| Profit Margin | -12.2% | -10.5% |
| EBITDA Margin | -7.85% | -2.67% |
| FCF Margin | 19.7% | 0.02% |
Returns
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -9.40% | -18.2% |
| Return on Assets (ROA) | -7.47% | -13.3% |
| Return on Invested Capital (ROIC) | -23.3% | -3.69% |
| Return on Capital Employed (ROCE) | -9.70% | -9.07% |
Growth
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -4.28% | 8.85% |
| FCF Growth (YoY) | 113.5% | 9.68% |
| Revenue Growth (3Y CAGR) | 7.57% | 7.08% |
| Revenue Growth (5Y CAGR) | 16.6% | 11.8% |
Balance sheet
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $552.03M | $36.66M |
| Net Cash (Debt) | $552.03M | $3.92M |
| Net Cash Per Share | $4.24 | $0.28 |
| Equity (Book Value) | $825.55M | $55.33M |
| Book Value Per Share | $6.34 | $2.87 |
| Tangible Book Value | $757.47M | $10.79M |
| Working Capital | $556.16M | $56.72M |
Financial position
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Current Ratio | 5.69 | 2.48 |
| Quick Ratio | 5.06 | 1.53 |
Cash flow (trailing twelve months)
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Operating Cash Flow | $127.09M | -$566.22K |
| Capital Expenditures | -$5.65M | -$3.69M |
| Free Cash Flow | $121.44M | -$696.00K |
| FCF Per Share | $0.93 | -$0.02 |
Efficiency
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Asset Turnover | 0.61 | 0.58 |
| Inventory Turnover | 3.04 | 2.21 |
| Revenue Per Employee | $523.69K | $322.92K |
| Profits Per Employee | -$63.77K | -$51.88K |
| Employee Count | 1,178 | 185 |
Dividends and yields
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Earnings Yield | -0.83% | -6.88% |
| FCF Yield | 1.33% | -0.45% |
Shares
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Shares Outstanding | 130,291,000 | 44,302,700 |
| Shares Change (YoY) | 4.38% | 3.36% |
| Float | 124,747,000 | 37,462,700 |
| Shares Held by Insiders | 4.26% | 10.5% |
| Shares Held by Institutions | 98.7% | 63.5% |
Taxes
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Income Tax | $235.00K | $1.52M |
Scores
| Measure | 10x Genomics | Industry median |
|---|---|---|
| Altman Z-Score | 25.58 | 1.95 |
| Piotroski F-Score | 6 | 5 |
| Beneish M-Score | -3.58 | -2.64 |
Calculated by StockData from 10x Genomics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.